Navigation Links
ChemDiv and Avineuro Extend Collaboration on Alzheimer's Disease and Schizophrenia
Date:11/21/2008

SAN DIEGO, Nov. 21 /PRNewswire/ -- ChemDiv Inc. and Avineuro Pharmaceuticals Inc. have extended the term of their research and development collaboration including formulation, safety and early clinical development studies in areas of neurodegenerative and psychiatric disorders. R&D services will be provided by Chemical Diversity Research Institute, ChemDiv's research subsidiary based in Moscow. The new agreement provides for research funding of clinical candidate compounds to POC. Avineuro is responsible for further clinical development and commercialization of drug candidates AVN101, AVN211, and additional compounds that may be nominated for development from the ongoing research and discovery under the agreement. In September, ChemDiv entered into an out-licensing and collaboration agreement with Avineuro to develop multiple compounds for Alzheimer Disease and schizophrenia. Under the agreement, Avineuro obtained exclusive worldwide rights to clinical development candidates AVN101, AVN211, and lead compounds in various stages of pre-clinical development. ChemDiv will provide pre-clinical development services to nominate additional backup leads and candidates for Avineuro.

About Avineuro Pharmaceuticals, Inc.:

Avineuro Pharmaceuticals, Inc. discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Founded in August 2008 and headquartered in San Diego, California, Avineuro is managed by seasoned professionals experienced in drug discovery and development. By acquiring lead compounds through collaborations and partnerships, Avineuro plans to develop novel products and extend the reach of marketed compounds for indications with a significant commercial potential. Avineuro emphasizes a rational approach that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candida
'/>"/>

SOURCE ChemDiv, Inc.; Avineuro Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ChemDiv and Achaogen Enter Into a Discovery Collaboration
2. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
3. Roche Extends Tender Offer for Ventana
4. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
5. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
6. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
7. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
8. ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook
9. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
10. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... sophisticated equipment, trained personnel, and detection dogs to ... attacks. A revolutionary new electronic chip with nano-sized ... much easier. , The groundbreaking nanotechnology-inspired sensor, devised ... ,s School of Chemistry and Center for Nanoscience ... Tracense, picks up the scent of explosives molecules ...
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Cell Culture Market 2014-2018" report to their ... Cell culture is the in vitro growth of ... research, cell studies, and biopharmaceutical production. Cell culture is ... Cell culture instruments and cell culture consumables are necessary ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Three companies ... semi-finalists in Livestrong’s Big C Competition. Out of 700 ... each headed to the semi-final round. In this round ... three-month accelerator program, complete with mentoring from thought-leaders and ... As part of the angelMD commitment to the Livestrong ...
(Date:7/24/2014)... The first part of the session on ... Human Studies” will cover comprehensive clinical support in early ... increasing R&D costs and declining industry success in getting ... knowledge collected in early Phase I/IIa study data to ... stage development. , Next, the presenters will examine steps ...
Breaking Biology Technology:Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced today ... Stearns 20th Annual Healthcare Conference on September,11, 2007 at ... the Grand,Hyatt Hotel in New York City. Jack Lief, ... a corporate overview of the,company and its clinical development ...
... Vical Incorporated,(Nasdaq: VICL ) today announced ... Conference will be webcast live on Monday, September ... and Chief Executive Officer,Vijay B. Samant, will provide ... strategic partnerships. The webcast will be,available live and ...
... ... 2007--, PALO ALTO, Calif., ... data published in Circulation and,presented at the European Society of Cardiology Congress ... atrial arrhythmias in patients receiving Ranexa,compared to placebo in the MERLIN TIMI-36 ...
Cached Biology Technology:Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 3Vical to Present at Upcoming Investor Conferences 2Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R) 2Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R) 3Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R) 4
(Date:7/25/2014)... the way for the development of new lines of barley ... production is second only to wheat with 7-8 million tonnes ... diseases of barley. , Senior Research Scientist Dr Alan Little ... the cell walls of barley plants that block the penetration ... the ARC Centre of Excellence in Plant Cell Walls in ...
(Date:7/25/2014)... MOResearchers at the Stowers Institute for Medical Research ... pheromone receptors, and found pheromones crucial to triggering the ... of receptors helps a male mouse detect pheromones that ... of receptors lets him know if the female mouse ... pheromones are critical to trigger mating. Stowers, researchers believe ...
(Date:7/24/2014)... leads to conflict among people around the world, a ... Health & Ecosystems: Analysis of Linkages (HEAL) Program Director ... tackle global biodiversity decline. , The harvest of wild ... and provides protein for more than a billion of ... that today,s unprecedented loss of wildlife, is bringing with ...
Breaking Biology News(10 mins):New hope for powdery mildew resistant barley 2It takes two to court 2It takes two to court 3New study draws links between wildlife loss and social conflicts 2
... (December 2nd, 2011) Most of us would agree that ... the journal Clinical Rehabilitation , published by SAGE, indicate ... on health grounds in Finland had no measurable effect. , ... rehabilitation, which followed 872 participants and their 2440 matched controls ...
... research hurdle to developing regenerative treatments for diabetes and ... amounts of endoderm cells from human pluripotent stem cells. ... can be transferred to other areas of stem cell ... use known as the ,valley of death,. "One ...
... implantable replacement cartilage, holding promise for knees, shoulders, ears ... Self-assembling sheets of mesenchymal stem cells permeated ... stiffer cartilage than previous tissue engineering methods, researchers at ... the research is published in the Journal of ...
Cached Biology News:Costly intervention program has no measurable effect on early retirement 2Costly intervention program has no measurable effect on early retirement 3Scalable amounts of liver and pancreas precursor cells created using new stem cell production method 2Engineering cartilage replacements 2Engineering cartilage replacements 3